<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450853</url>
  </required_header>
  <id_info>
    <org_study_id>GRA / SC-IV</org_study_id>
    <nct_id>NCT00450853</nct_id>
  </id_info>
  <brief_title>Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients</brief_title>
  <official_title>Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated With Platinum Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: to evaluate the bioavailability of subcutaneous granisetron.Patients receiving
      platinum-based chemotherapy will be randomized to receive granisetron 3 mg either
      subcutaneously or intravenously in a crossover manner during two cycles. Blood and urine
      samples will be collected after each cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-HT3 antagonists are one of the mainstays of antiemetic treatment and they are administered
      either intravenously or orally. Nevertheless sometimes neither administration route is
      feasible, such as in patients unable to admit oral intake managed in an outpatient setting.
      Our objective is to evaluate the bioavailability of subcutaneous granisetron.Patients
      receiving platinum-based chemotherapy will be randomized to receive granisetron 3 mg either
      subcutaneously or intravenously in a crossover manner during two cycles. Blood and urine
      samples will be collected after each cycle. Pharmacokinetics of SC and IV granisetron will be
      prospectively compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Granisetron SC-Granisetron IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Granisetron SC followed by Granisetron IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>granisetron</intervention_name>
    <description>Granisetron SC followed by granisetron IV</description>
    <arm_group_label>Granisetron SC-Granisetron IV</arm_group_label>
    <other_name>Granisetron SC followed by granisetron IV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer patients receiving platinum-based chemotherapy

          -  adequate bone marrow, hepatic and renal function, respectively defined by: platelets
             &gt;100000/mm3 and absolute neutrophil count &gt;1500/mm3; bilirubin, AST and ALT &lt;2 times x
             upper limit of normality; and creatinine &lt;1.5 mg/dl.

          -  ECOG performance status &lt;2 and body mass index from 20-28 kg/m2.

        Exclusion Criteria:

          -  Pregnancy

          -  Serious concomitant diseases, in the invesgatorÂ´s criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Gurpide</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Department. Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Universidad de Navarra, Universidad de Navarra</investigator_affiliation>
    <investigator_full_name>Jose Luis Perez Gracia</investigator_full_name>
    <investigator_title>Main investigator</investigator_title>
  </responsible_party>
  <keyword>emesis</keyword>
  <keyword>granisetron</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>subcutaneous.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

